商务部等9部门：鼓励创新药、参比制剂等药品进零售药店销售渠道

Core Viewpoint - The document outlines the opinions from the Ministry of Commerce and nine other departments aimed at promoting high-quality development in the pharmaceutical retail industry, emphasizing the need for an optimized marketing system and fair competition across regions [1] Group 1: Marketing System Optimization - The opinions advocate for deep collaboration between pharmaceutical manufacturers and large national or regional pharmaceutical distribution companies, focusing on market-oriented regulation of drug purchase and sales pricing systems [1] - There is a push to encourage the sale of innovative drugs and reference preparations through retail pharmacies [1] Group 2: Competition and Pricing - The document promotes fair competition in the pharmaceutical retail industry across provinces and regions, guiding retail drug prices to remain at reasonable levels [1] - It encourages the opening of data interfaces by pharmaceutical e-commerce platforms to enhance monitoring of online and offline drug retail prices in relation to provincial medical procurement platform prices [1] Group 3: Technology and Data Utilization - The opinions highlight the importance of promoting the application of price comparison indices for designated pharmacies and drug price comparison mini-programs [1]